Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Respirar (Ciudad Autón. B. Aires) ; 16(1): 17-21, Marzo 2024.
Article in Spanish | LILACS, UNISALUD, BINACIS | ID: biblio-1551135

ABSTRACT

Introducción: Los leiomiomas uterinos son un tipo de neoplasia benigna de frecuente aparición en mujeres de edad reproductiva, relacionados con enfermedad tromboem- bólica venosa. Este vínculo surge del efecto producido por la compresión de fibromas que genera estasis venosa en la región pelviana. Sin embargo, este pareciera no ser el único factor que lo relaciona con el desarrollo posterior de hipertensión pulmonar, sino que su presencia es gatillo de una serie de fenómenos que influyen sobre la vasculatu - ra pulmonar y también a nivel sistémico. Método: Revisión de una serie de casos (seis) atendidos en nuestra unidad, seguido de una revisión sobre la relación entre leiomio- mas y distintas formas de hipertensión pulmonar con una revisión desde la fisiopatología. Resultado y conclusiones: Encontramos sustento bibliográfico en los múltiples caminos fisiopatológicos que relacionan los mediadores vasculares comunes, que parecieran ser el punto clave en la relación entre estas dos patologías.


Introduction: Uterine leiomyomas are a type of benign neoplasm that frequently appears in women of reproductive age, related to venous thromboembolic disease. This link arises from the effect produced by the compression of fibroids, which generates venous stasis in the pelvic region. However, this seems not to be the only factor that re- lates it to the subsequent development of pulmonary hypertension, but rather its presence is a trigger for a series of phenomena that influence the pulmonary vasculature and also at a systemic level. Method: Review of a series of cases (six) cared for in our unit, followed by a review on the relationship between leiomyomas and different forms of pulmonary hypertension with a review from the pathophysiology. Result and conclusions: We found bibliographic support in the multiple pathophysiological paths that relate the common vascular mediators, which appear to be the key point in the relationship between these two pathologies.


Subject(s)
Humans , Female , Adult , Middle Aged , Uterine Neoplasms/physiopathology , Venous Thromboembolism/physiopathology , Hypertension, Pulmonary/physiopathology , Leiomyoma/physiopathology , Echocardiography , Cardiac Catheterization/methods , Biomarkers , Review , Computed Tomography Angiography/methods
2.
Pediatr Crit Care Med ; 22(3): e178-e191, 2021 03 01.
Article in English | MEDLINE | ID: mdl-33003176

ABSTRACT

OBJECTIVES: The disease caused by severe acute respiratory syndrome coronavirus 2, known as coronavirus disease 2019, has resulted in a global pandemic. Reports are emerging of a new severe hyperinflammatory syndrome related to coronavirus disease 2019 in children and adolescents. The Centers for Disease Control and Prevention has designated this disease multisystem inflammatory syndrome in children. Our objective was to develop a clinical inpatient protocol for the evaluation, management, and follow-up of patients with this syndrome. DATA SOURCES: The protocol was developed by a multidisciplinary team based on relevant literature related to coronavirus disease 2019, multisystem inflammatory syndrome in children, and related inflammatory syndromes, as well as our experience caring for children with multisystem inflammatory syndrome in children. Data were obtained on patients with multisystem inflammatory syndrome in children at our institution from the pre-protocol and post-protocol periods. DATA SYNTHESIS: Our protocol was developed in order to identify cases of multisystem inflammatory syndrome in children with high sensitivity, stratify risk to guide treatment, recognize co-infectious or co-inflammatory processes, mitigate coronary artery abnormalities, and manage hyperinflammatory shock. Key elements of evaluation include case identification using broad clinical characteristics and comprehensive laboratory and imaging investigations. Treatment centers around glucocorticoids and IV immunoglobulin with biologic immunomodulators as adjuncts. Multidisciplinary follow-up after discharge is indicated to manage continued outpatient therapy and evaluate for disease sequelae. In nearly 2 months, we admitted 54 patients with multisystem inflammatory syndrome in children, all of whom survived without the need for invasive ventilatory or mechanical circulatory support. After institution of this protocol, patients received earlier treatment and had shorter lengths of hospital stay. CONCLUSIONS: This report provides guidance to clinicians on evaluation, management, and follow-up of patients with a novel hyperinflammatory syndrome related to coronavirus disease 2019 known as multisystem inflammatory syndrome in children. It is based on the relevant literature and our experience. Instituting such a protocol during a global pandemic is feasible and is associated with patients receiving treatment and returning home more quickly.


Subject(s)
COVID-19 , Adolescent , Child , Follow-Up Studies , Humans , New York City , SARS-CoV-2 , Syndrome , Systemic Inflammatory Response Syndrome
3.
Pediatr Crit Care Med ; 22(2): e125-e134, 2021 02 01.
Article in English | MEDLINE | ID: mdl-33027239

ABSTRACT

OBJECTIVES: The current novel severe acute respiratory syndrome coronavirus 2 outbreak has caused an unprecedented demand on global adult critical care services. As adult patients have been disproportionately affected by the coronavirus disease 2019 pandemic, pediatric practitioners world-wide have stepped forward to support their adult colleagues. In general, standalone pediatric hospitals expanded their capacity to centralize pediatric critical care, decanting patients from other institutions. There are few units that ran a hybrid model, managing both adult and pediatric patients with the same PICU staff. In this report, we describe the hybrid model implemented at our respective institutions with shared experiences, pitfalls, challenges, and adjustments required in caring for both young and older patients. DESIGN: Retrospective cohort study. SETTING: Two PICUs in urban tertiary hospitals in London and New York. PATIENTS: Adult and pediatric patients admitted to the PICU in roughly a 6-week period during the coronavirus disease 2019 surge. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The PICU at King's College Hospital admitted 23 non-coronavirus disease adult patients, while whereas the PICU at Morgan Stanley's Children Hospital in New York admitted 46 adults, 30 of whom were coronavirus disease positive. The median age of adult patients at King's College Hospital was higher than those admitted in New York, 53 years (19-77 yr) and 24.4 years (18-52 yr), respectively. Catering to the different physical, emotional, and social needs of both children and adults by the same PICU team was challenging. One important consideration in both locations was the continued care of patients with severe non-coronavirus disease-related illnesses such as neurosurgical emergencies, trauma, and septic shock. Furthermore, retention of critical specialists such as transplant services allowed for nine and four solid organ transplants to occur in London and New York, respectively. CONCLUSIONS: This hybrid model successfully allowed for the expansion into adult critical care while maintaining essential services for critically ill children. Simultaneous care of adults and children in the ICU can be sustained if healthcare professionals work collaboratively, show proactive insight into anticipated issues, and exhibit clear leadership.


Subject(s)
COVID-19 , Adult , Child , Critical Care , Humans , Infant , Intensive Care Units, Pediatric , London/epidemiology , Middle Aged , New York , Retrospective Studies , SARS-CoV-2 , Tertiary Care Centers
4.
ACS Appl Mater Interfaces ; 12(16): 18885-18892, 2020 Apr 22.
Article in English | MEDLINE | ID: mdl-32233387

ABSTRACT

The metal-organic framework (MOF)-type MFM-300(Sc) exhibits a combined physisorption and chemisorption capture of H2S, leading to a high uptake (16.55 mmol g-1) associated with high structural stability. The irreversible chemisorbed sulfur species were identified as low-order polysulfide (n = 2) species. The isostructural MFM-300(In) was demonstrated to promote the formation of different polysulfide species, paving the way toward a new methodology to incorporate polysulfides within MOFs for the generation of novel MOF-lithium/sulfur batteries.

5.
Mem. Inst. Invest. Cienc. Salud (Impr.) ; 17(1): 6-15, abr. 2019. ilus, tab
Article in Spanish | LILACS, BDNPAR | ID: biblio-1007859

ABSTRACT

En Paraguay la incidencia de cáncer de cuello uterino (CCU) es superior a las observadas en otros países de la región. El agente etiológico asociado al CCU es el virus papiloma humano (VPH), esencialmente tipos de alto riesgo oncogénicos. El objetivo es describir aspectos epidemiológicos de la infección genital por el virus papiloma humano de alto riesgo (VPH-AR) en mujeres de 25 a 64 años que consultaron en servicios de Patología Cervical del MSPyBS, de mayo a diciembre de 2013. Se utilizó el Cobas 4800 HPV Test (Roche) que permite la detección individual de VPH-16 y VPH-18 y un pool de otros VPH-AR que incluye 12 genotipos de alto riesgo. Los otros VPH-AR fueron tipificados por hibridación reversa en línea (RLB). Entre las 495 mujeres incluidas, se detectaron 72 casos positivos (14,5%) de VPH-AR. Se identificaron 19 tipos virales; siendo el más frecuente VPH-16 (2,1%), seguido del VPH-31, 33, 58 y 66; el VPH-18 aparece en sexto lugar. Este trabajo aporta los primeros datos sobre la implementación de técnicas moleculares para detección y tipificación de VPH como parte del sistema de salud pública de Paraguay. El predominio de VPH-16, confirma su amplia circulación a nivel mundial y dado su mayor potencial oncogénico, representa una alerta a considerar, en especial en las mujeres mayores de 30 años portadoras de una infección persistente. Estos resultados apoyan la importancia de la implementación criteriosa y la utilización apropiada de las pruebas moleculares actualmente disponibles para la prevención y control del CCU(AU)


Subject(s)
Humans , Female , Adult , Middle Aged , Papillomaviridae/genetics , Uterine Cervical Neoplasms/epidemiology , Uterine Cervical Neoplasms/virology , Papillomavirus Infections/epidemiology , Papillomavirus Infections/virology , Paraguay/epidemiology , Cross-Sectional Studies , Human papillomavirus 16/genetics , Human papillomavirus 18/genetics , Genotyping Techniques
6.
Mem. Inst. Invest. Cienc. Salud (Impr.) ; 14(1): 64-69, abr. 2016. tab
Article in Spanish | LILACS, BDNPAR | ID: biblio-869071

ABSTRACT

El cáncer de cuello uterino (CCU) es la primera causa de muerte por cáncer en mujeres en países en vías de desarrollo. La infección persistente por el virus papiloma humano (VPH) es un factor necesario en lesiones preneoplásicas y CCU. La citología cervicovaginal es el método mayormente utilizado para detectar el CCU y su uso combinado con la de detección de ADN viral seis meses post-tratamiento aumenta la efectividad para identificar mujeres tratadas con riesgo de lesión residual/recidiva. El objetivo fue describir la frecuencia de VPH de alto riesgo (AR) en mujeres tratadas por lesión escamosa intraepitelial (SIL) que acudieron al Servicio de Patología Cervical del Hospital San Pablo de enero-diciembre/2014. Se realizó un estudio descriptivo de corte transverso, que incluyó 80 pacientes que acudieron al servicio para control post-tratamiento por SIL. Se utilizó Cobas 4800 HPV Test (Roche) para la detección individual de VPH-16 y 18, y un pool de 10 VPH-AR (31,33,35,39,45,51,52,56,58,59) y dos de “probable” alto riesgo (66,68). Se encontró infección viral en el 7,5% (6/80) de las pacientes tratadas; identificándose VPH-16 en 3/6 de los casos positivos. En Paraguay existe alta incidencia de lesiones pre-neoplásicas y CCU siendo un problema de salud pública. Los datos observados sugieren que la utilización de este sistema para la detección viral puede llevar a optimizar el seguimiento post-tratamiento y la identificación de VPH-16 y 18 podría contribuir a la selección de pacientes en mayor riesgo de desarrollar una lesión cervical que deben someterse a una vigilancia frecuente y meticulosa.


Cervical cancer is the leading cause of cancer death in women in developing country.Persistent infection with human papillomavirus (HPV) is a necessary factor in premalignantlesions and cervical cancer. The Pap smear is the method most commonly used to detect thecervical cancer and its combined with the detection of viral DNA six months post-treatment increases effectiveness to identify women treated in risk with residual/recurrent lesion. Theaim was to describe the frequency of high-risk HPV (HR) in treated women for squamousintraepithelial lesion (SIL) who attended the Cervical Pathology Service of Hospital San Pablofrom January to December/2014. It is cross sectional, descriptive study which included 80patients who attended the service for post-treatment control. The 4800 Cobas HPV Test(Roche) was used, which detects HPV-16 and 18, and a pool of 10 HR-HPV(31,33,35,39,45,51,52,56,58,59) and two "probable" high risk (66,68). Viral infection wasfound in 7.5% (6/80) of patients treated; identifying HPV-16 in 3/6 of positive cases. InParaguay there is a high incidence of pre-neoplastic lesions and cervical cáncer remains apublic health problem. The observed data suggest that the use of this system for viraldetection can lead to optimize the post-treatment monitoring and the identification of HPV-16and 18 could contribute to the selection of patients at increased risk of developing cervicalinjury should undergo to frequent and careful monitoring.


Subject(s)
Humans , Adult , Female , Middle Aged , Uterine Cervical Dysplasia , Papillomavirus Infections
7.
Mem. Inst. Invest. Cienc. Salud (Impr.) ; 13(3): 96-102, dic. 2015. tab
Article in Spanish | LILACS, BDNPAR | ID: biblio-869053

ABSTRACT

La hepatitis B es un grave problema de salud pública a nivel mundial, aproximadamente cerca de 2 billones de personas tienen evidencia serológica de infección por el virus de la hepatitis B. El objetivo de este trabajo fue describir la frecuencia de hepatitis B e identificar los factores de riesgo asociados en mujeres en edad fértil que acudieron al Laboratorio Central de Salud Pública entre diciembre de 2013 y junio de 2014. Fue un estudio observacional analítico de corte transverso que, previo consentimiento informado, analizó suero de mujeres entre 15 y 44 años con una edad promedio de 26,6 (±6,8) años. Mediante la detección del antígeno de superficie de la hepatitis B por ELISA se identificaron seis casos positivos (0,4%), indicando una endemicidad baja; cifra que ha variado según perfil socio demográfico: según edad, las de 20 y más años presentaron una frecuencia mayor en comparación a las demás (p>0,05). No se observaron diferencias significativas al evaluar la seropositividad según el estado civil, el nivel de escolaridad, la condición de gravidez, los antecedentes de transfusiones, sin embargo, la seropositividad era mayor en las portadoras de tatuajes/piercing que entre las no portadoras, lo que representaba un riesgo 6,2 veces mayor (OR:6,2 IC95%:1,3-31,3). En conclusión, la frecuencia del HBsAg en nuestra población es baja, y el factor de riesgo asociado a su detección fue la presencia de tatuajes y/o piercing.


Hepatitis B is a serious public health problem worldwide; approximately about 2 billionpeople have serologic evidence of infection with hepatitis B virus. The aim of this analyticcross-sectional study was to describe the frequency of hepatitis B and identify risk factorsin women of child bearing age who attended the Central Public Health Laboratory in theperiod 2013 to 2014. Prior informed consent, antigen detection of hepatitis B surface wasperformed by ELISA in women between 15 and 44 years with a mean age of 26.6 (±6.8)years. The identification of six serologic positive cases (0.4%) indicates low endemicity.This figure varied according to socio-demographic profile: according to age, those whowere 20 years old or older had an increased frequency compared to the others (p> 0.05). No significant differences were observed in seropositivity by marital status, level ofeducation, pregnancy, history of transfusion, while seropositivity was higher amongcarriers of tattoos/piercing than among non-carriers, which represented a 6.2 times higherrisk (OR 6.2 95% CI 1.3 to 31.3). In conclusion, the frequency of HBsAg in our populationwas low. The risk factor associated with its detection was the presence of tattoos and / or piercings.


Subject(s)
Humans , Adult , Female , Middle Aged , Hepatitis B , Hepatitis B virus , Public Health
8.
Endocrinol. nutr. (Ed. impr.) ; 57(10): 486-491, dic. 2010. ilus, tab
Article in Spanish | IBECS | ID: ibc-118286

ABSTRACT

Objetivo Distintos estudios ya han señalado la prevalencia importante de disfunción tiroidea inducida por sunitinib. No obstante, se desconoce el mecanismo de acción subyacente y el beneficio del tratamiento sustitutivo. Con el objeto de evaluar la función tiroidea en los pacientes con carcinoma de células renales avanzado tratados con sunitinib, se realizó el estudio descriptivo presentado. Material y métodos Se incluyeron 24 pacientes tratados entre 2006 y 2008 en el Hospital Clínico San Carlos. Los datos recogidos de forma retrospectiva se analizaron con el paquete estadístico SPSS 15.0.ResultadosLa duración del tratamiento fue de 30 (18–42) semanas (mediana [RIQ]). Cinco pacientes (20,8%) desarrollaron hipotiroidismo subclínico, y 3 (12,5%) hipotiroidismo clínico. El número de semanas necesarias para observar elevación de TSH fue 15 (6–20) (mediana [RIQ]). Cinco pacientes (20,8%) presentaron TSH disminuida previa al tratamiento o durante el mismo, sin poder establecer el diagnóstico de hipertiroidismo subclínico dados los factores intercurrentes. Catorce pacientes (58,3%) presentaron toxicidad, sin encontrarse una asociación con el desarrollo de hipotiroidismo (p=0,388).Conclusiones La elevada prevalencia de hipotiroidismo inducido por sunitinib hace necesario un seguimiento sistemático de la función tiroidea en estos pacientes. No obstante, dicho estudio puede estar interferido por distintos factores fisiopatológicos y farmacológicos, por lo que podría ser útil determinar no solo TSH y T4 libre, sino también T3 libre e, idealmente, T3 reversa. A día de hoy carecemos de recomendaciones para el manejo del hipotiroidismo en el paciente oncológico basadas en la evidencia (AU)


Objective Several studies have reported the substantial prevalence of sunitinib-induced thyroid dysfunction. However, the underlying mechanism and the benefit of thyroid hormone replacement therapy remain to be determined. To evaluate the effect of sunitinib on thyroid function, we carried out a descriptive study in patients with advanced renal cell carcinoma. Patients and methods A total of 24 patients treated by sunitinib between 2006 and 2008 at Hospital Clínico San Carlos were included. The data were collected retrospectively and analyzed with SPSS 15.0.ResultsTreatment duration was 30 weeks (18–42) [median (IQR)]. Five patients (20.8%) developed subclinical hypothyroidism and three (12.5%) developed overt hypothyroidism. The number of weeks needed to observe an increase in thyroid-stimulating hormone (TSH) values in these patients was 15 (6–20) [median (IQR)]. TSH levels were below the normal range in five patients (20.8%) before or during the treatment period, but the diagnosis of subclinical hyperthyroidism could not be established because of concomitant factors. Fourteen patients (58.3%) showed sunitinib adverse events, but these were not related to the development of hypothyroidism (p=0.388).Conclusions Because of the high prevalence of sunitinib-induced hypothyroidism, thyroid function should be systematically monitored in patients with renal cell carcinoma treated with this drug. However, several pathophysiological and pharmacological factors may interfere with monitoring. Consequently, it might be useful to determine not only TSH and free T4 but also free T3 and, ideally, reverse T3. Evidence-based recommendations to manage hypothyroidism in oncology patients are not available at present (AU)


Subject(s)
Humans , Carcinoma, Renal Cell/complications , Kidney Neoplasms/complications , Thyroid Diseases/chemically induced , /adverse effects , Glucocorticoids/therapeutic use , Thyroid Function Tests , Thyroid Hormones , Euthyroid Sick Syndromes/epidemiology
9.
Endocrinol Nutr ; 57(10): 486-91, 2010 Dec.
Article in Spanish | MEDLINE | ID: mdl-20702151

ABSTRACT

OBJECTIVE: Several studies have reported the substantial prevalence of sunitinib-induced thyroid dysfunction. However, the underlying mechanism and the benefit of thyroid hormone replacement therapy remain to be determined. To evaluate the effect of sunitinib on thyroid function, we carried out a descriptive study in patients with advanced renal cell carcinoma. PATIENTS AND METHODS: A total of 24 patients treated by sunitinib between 2006 and 2008 at Hospital Clínico San Carlos were included. The data were collected retrospectively and analyzed with SPSS 15.0. RESULTS: Treatment duration was 30 weeks (18-42) [median (IQR)]. Five patients (20.8%) developed subclinical hypothyroidism and three (12.5%) developed overt hypothyroidism. The number of weeks needed to observe an increase in thyroid-stimulating hormone (TSH) values in these patients was 15 (6-20) [median (IQR)]. TSH levels were below the normal range in five patients (20.8%) before or during the treatment period, but the diagnosis of subclinical hyperthyroidism could not be established because of concomitant factors. Fourteen patients (58.3%) showed sunitinib adverse events, but these were not related to the development of hypothyroidism (p=0.388). CONCLUSIONS: Because of the high prevalence of sunitinib-induced hypothyroidism, thyroid function should be systematically monitored in patients with renal cell carcinoma treated with this drug. However, several pathophysiological and pharmacological factors may interfere with monitoring. Consequently, it might be useful to determine not only TSH and free T4 but also free T3 and, ideally, reverse T3. Evidence-based recommendations to manage hypothyroidism in oncology patients are not available at present.


Subject(s)
Antineoplastic Agents/adverse effects , Carcinoma, Renal Cell/drug therapy , Hypothyroidism/chemically induced , Indoles/adverse effects , Kidney Neoplasms/drug therapy , Protein Kinase Inhibitors/adverse effects , Pyrroles/adverse effects , Aged , Antineoplastic Agents/therapeutic use , Carcinoma, Renal Cell/complications , Carcinoma, Renal Cell/pathology , Humans , Hypothyroidism/blood , Hypothyroidism/epidemiology , Indoles/therapeutic use , Kidney Neoplasms/complications , Kidney Neoplasms/pathology , Middle Aged , Prevalence , Protein Kinase Inhibitors/therapeutic use , Pyrroles/therapeutic use , Retrospective Studies , Sunitinib , Thyroid Hormones/blood , Thyrotropin/blood
10.
Prensa méd. argent ; 91(6): 423-433, 2004. tab
Article in Spanish | BINACIS | ID: bin-3140

ABSTRACT

This study aimed to analyze the pharmacological management of primary pulmonary arterial hypertension (PPH). PPH has been considered during a long time, an incurable disease...The purpose of this report is to present an evaluation fo these new pharmacological tools and approaches more suitables for widespread application in the future


Subject(s)
Humans , Hypertension, Pulmonary/therapy , Hypertension, Pulmonary/drug therapy , Cardiology , Pharmacology, Clinical
11.
Prensa méd. argent ; 91(6): 423-433, 2004. tab
Article in Spanish | LILACS | ID: lil-391382

ABSTRACT

This study aimed to analyze the pharmacological management of primary pulmonary arterial hypertension (PPH). PPH has been considered during a long time, an incurable disease...The purpose of this report is to present an evaluation fo these new pharmacological tools and approaches more suitables for widespread application in the future


Subject(s)
Humans , Hypertension, Pulmonary/drug therapy , Hypertension, Pulmonary/therapy , Cardiology , Pharmacology, Clinical
12.
Asunciòn; EFACIM-EDUNA; 1997. 175-181 p.
Monography in Spanish | LILACS, BDNPAR | ID: biblio-1018372

ABSTRACT

La enfermedad de Graves Basedow es una enfermedad autoinmune organoespecìfica ocasionalmente asociada a LES. Como dicha coincidencia mòrbida la conocìamos a travès de publicaciones aisladas, quisimos comunicar el caso de una niña de 12 años con enfermedad de Graves Basedow tratada quirùrgicamente, que desarrollò a los pocos meses de la tiroidectomìa una nefropatìa lùpica.


Subject(s)
Graves Disease , Lupus Vulgaris/nursing , Thyroiditis, Autoimmune/nursing
13.
Asunciòn; EFACIM-EDUNA; 1997. s.p
Monography in Spanish | LILACS | ID: lil-228370

ABSTRACT

La enfermedad de Graves Basedow es una enfermedad autoinmune organoespecìfica ocasionalmente asociada a LES. Como dicha coincidencia mòrbida la conocìamos a travès de publicaciones aisladas, quisimos comunicar el caso de una niña de 12 años con enfermedad de Graves Basedow tratada quirùrgicamente, que desarrollò a los pocos meses de la tiroidectomìa una nefropatìa lùpica


Subject(s)
Graves Disease , Lupus Vulgaris/nursing , Thyroiditis, Autoimmune/nursing
14.
Asunción; EDUNA; 1995. 135-44 p. tab.
Monography in Spanish | LILACS, BDNPAR | ID: lil-219983

ABSTRACT

Con el propósito de evaluar la protección biológica contra la infección experimental de T. cruzi, se inocularon ratones "Pearl bright" con la proteina recombinante inmunoprotectora JL7 (Frasch, 1991). La proteina JL7 fué aislada originalmente por Levín y colaboradores (Levin et al. 1989) y cedida al IICS para su desarrollo y evaluación en éste estudio. En el protocolo experimental se utilizaron 5 lotes de ratones: 3 sometidos a infección a Trypanosoma cruzi (controles, inoculados con soponina e inoculados con JL7 + saponina) y 2 lotes donde se testaron la saponina y la proteína JL7. Los parámetros que se utilizaron para la evaluación fueron parasitemia, mortalidad, respuesta inmunológica e invasión tisular. Se utilizó la técnica del Dot blot para determinar anticuerpos JL7, evaluándose los grupos de JL7 en 3 oportunidades. Las inmunizaciones se realizaron cada 15 días por via i.p. con 80 ug de JL7 ug de saponina. Los ratones se infectaron con 50.000 parásitos de la cepa Y, 30 días después de la última inmunización. Los animales que murieron en el transcurso de la infección fueron remitidos para estudios anatomopatológicos y los sobrevivientes se sacrificaron un mes después de la infección, para ser sometidos a la misma inspección. Los ratones inmunizados alcanzaron una respuesta inmunitaria en ambos grupos del 67 por ciento 30 días después de la primera inmunización, llegando a un 100 por ciento después de 30 días de la infección. La parasitemia fué similar en todos los grupos, al igual que la mortalidad (4 ratones en los grupos Control y saponina, 3 el de JL7). Todos los ratones que murieron durante el ensayo presentaron nidos de T. cruzi en el corazón, colon, esófago, estómago y peritoneo, y reacción inflamatoria mononuclear en corazón y colon. En los animales sagrificados inoculados con JL7 no se encontraron parásitos en el corazón, a diferencia de los otros grupos. Los datos obtenidos nos muestran que la proteina JL7 a la dosis utilizada provocó una respuesta inmunológica pero que los anticuerpos no protegieron a los ratones de la infección experimental. Sin embargo, el hecho de no encontrar parásitos en el corazón de los ratones inoculados con JL7 nos induce a pensar que aumento la cantidad de proteina inoculada, modificando el esquema de inmunización y el número de parásitos inoculados, se obtendría un grado de protección más significativo


Subject(s)
Trypanosoma cruzi/immunology , Chagas Disease/nursing , Chagas Disease/parasitology , Immunity/immunology , Recombinant Proteins/immunology , Recombinant Proteins , Recombinant Proteins/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...